Improvement in Liver Function Tests in Those with ALDH2 Deficiency After Taking Essential AD2 for 28 days
Clinical Results: In Liver Function Tests, Essential AD2 decreased AST and ALT which, when high, are indicators of liver damage or disease.
Liver Health and Acetaldehyde
The liver is responsible for the breakdown of the acetaldehyde toxin. Acetaldehyde damages the liver by causing scarring, which is also called fibrosis. Over time, this scarring decreases liver function. Continued damage to the liver from acetaldehyde leads to liver disease, cirrhosis, and cancer of the liver. Alcohol consumption is a major source of acetaldehyde, which is why many drinkers, and particularly those with ALDH2 Deficiency, are at high risk of liver disease. In addition to causing fibrosis, acetaldehyde damages DNA directly, which is why it can lead to cancer.
The more acetaldehyde exposure over time, the higher the risk of long-term damage and disease. Acetaldehyde’s ability to cause liver damage is very well established. In those with ALDH2 Deficiency, acetaldehyde levels can be 10 to 20x higher than normal, which is why low ALDH2 activity has been shown to increase risk of certain diseases.
Essential AD2 is the only product clinically proven to reduce acetaldehyde build-up in the body. Essential AD2 protects the liver by reducing exposure to acetaldehyde. The antioxidants in Essential AD2 boost the liver's ability to detoxify acetaldehyde.
In a clinical study of Essential AD2, liver function was measured before and after 28 days of supplementing with Essential AD2 in those with ALDH2 Deficiency. Two liver enzymes, Alanine transaminase (ALT) and Aspartate transaminase (AST), were used to measure liver function. Doctors use these enzymes as indicators of liver damage or disease, and together they are known as Liver Function Tests. Inflamed or injured livers release higher than normal amounts of these enzymes into the blood.
Over the 28 day period, average AST and ALT measurements decreased from 27.3 to 15.2 and 20.9 to 13.2, respectively (see Figure 1).
The full article has been submitted to the American Journal of Therapeutics and will be published soon.